Table 1.
Clinical and Demographic Features of 44 Patients with Suspected Anabolic Steroid Jaundice
| Feature | Number Positive or median | Proportion or range |
|---|---|---|
| Sex (male) | 44 | 100% |
| Age (years) | 31.5 | 21–59 |
| Self-reported race | ||
| White/Caucasian | 36 | 82% |
| Black/African American | 5 | 11% |
| Asian-American | 1 | 2 % |
| Other/Multiracial | 2 | 5% |
| Weight (kg) [n=43]* | 88.2 | 50.5–117.1 |
| BMI (kg/m2) [n=43]* | 26.2 | 19.9–37.4 |
| Pre-Existing Conditions | ||
| Diabetes/Endocrine Ds | 0 | 0% |
| Alcohol use [n=43]* | 35 | 81% |
| HCV RNA positive [n=43]* | 3 | 8% |
| HIV positive | 1 | 2% |
| Family history liver ds | 1 | 2% |
| Body building supplement latency (months) | 2.5 | 0.45–15.5 |
| Signs and Symptoms | ||
| Jaundice | 44 | 100% |
| Pruritus | 37 | 84% |
| Abdominal Pain | 26 | 59% |
| Nausea | 27 | 61% |
| Rash | 11 | 25% |
| Fever | 7 | 16% |
• Data not available on all 44 patients; number given in brackets